January 17, 2025 07:02 AM EST
R&D

As­traZeneca wins BTK race to mar­ket in first-line man­tle cell lym­phoma

Elizabeth Cairns

Senior biopharma journalist

As­traZeneca’s Calquence be­came the first BTK in­hibitor ap­proved in the US for first-line use in man­tle cell lym­phoma on Thurs­day. The drug

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

No­vo claims high-dose Phase 3 We­govy win but sales im­pact might be mut­ed

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Af­ter three-month de­lay, Am­gen’s Lumakras clinch­es FDA green light in col­orec­tal can­cer

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

A service from the Financial Times